A 83-01: Selective ALK-5 Inhibitor for TGF-β Pathway Modulation

Executive Summary: A 83-01 is a small-molecule inhibitor with nanomolar potency against the TGF-β type I receptor (ALK-5) and additional inhibitory activity for ALK-4 and ALK-7 (IC50 ≈ 12 nM, measured in Mv1LuR4-2 cells) (APExBIO). It suppresses ALK-5-mediated Smad-dependent transcription without significantly affecting BMP-induced pathways at ≤1 μM. In organoid and fibrosis models, A 83-01 enables precise modulation of cellular differentiation and proliferation (Saito et al., 2025). The compound is highly soluble in DMSO (≥21.1 mg/mL) but insoluble in water, requiring careful stock preparation and storage below -20°C. Its selectivity, reproducibility, and purity (>98% by HPLC, MS, NMR) make A 83-01 a critical tool for TGF-β pathway research and translational studies (A 83-01: Selective ALK-5 Inhibitor).

Biological Rationale

The TGF-β signaling pathway orchestrates essential processes in development, tissue homeostasis, fibrosis, and cancer progression (Saito et al., 2025). Activation of TGF-β receptors, particularly ALK-5 (TGFBR1), drives Smad2/3 phosphorylation and downstream transcriptional responses. Dysregulation of this pathway is implicated in epithelial-mesenchymal transition (EMT), fibrotic disease, and metastatic progression. In vitro and organoid models require precise tools to modulate TGF-β activity to dissect these mechanisms. A 83-01, by selectively inhibiting ALK-5, allows researchers to decouple TGF-β-driven processes from related pathways such as BMP signaling. This selectivity is critical for modeling stem cell differentiation, fibrosis, and tumor microenvironment signaling with high fidelity.

Mechanism of Action of A 83-01 (ALK inhibitor)

A 83-01 is a highly selective small-molecule kinase inhibitor targeting the ATP-binding pocket of ALK-5 (TGF-β type I receptor) with an IC50 of approximately 12 nM in cellular reporter assays (APExBIO). The compound also inhibits ALK-4 and ALK-7 but exhibits minimal off-target activity at recommended concentrations (≤1 μM). Upon TGF-β ligand binding, ALK-5 phosphorylates receptor-regulated Smads (Smad2/3), which translocate to the nucleus to regulate gene expression. A 83-01 blocks ALK-5 kinase activity, preventing Smad2/3 phosphorylation and subsequent transcriptional activation. In Mv1LuR4-2 cell-based luciferase assays, 1 μM A 83-01 reduced ALK-5-induced luciferase reporter activity by 68%, confirming potent inhibitory function (APExBIO). The compound does not significantly inhibit BMP4-induced transcriptional activity at 1 μM, but modest suppression occurs above 3 μM, delineating its effective window for use in TGF-β-specific studies.

Evidence & Benchmarks

• A 83-01 suppresses ALK-5-mediated Smad-dependent luciferase reporter activity by 68% at 1 μM in Mv1LuR4-2 cells (APExBIO).
• The compound inhibits TGF-β/ALK-5 signaling with an IC50 of ~12 nM, as measured by Smad2/3 phosphorylation assays (APExBIO).
• In hiPSC-derived intestinal organoid cultures, selective TGF-β pathway inhibition by A 83-01 supports robust epithelial cell differentiation and minimizes unwanted mesenchymal transition (Saito et al., 2025).
• A 83-01 exhibits minimal inhibition of BMP4-induced transcriptional activity at 1 μM, but partial suppression at concentrations ≥3 μM, indicating a concentration-dependent selectivity window (APExBIO).
• Purity of A 83-01 is confirmed to exceed 98% by HPLC, MS, and NMR analyses, supporting experimental reproducibility (APExBIO).

For more in-depth analysis of A 83-01's mechanistic impact, see this article on fibrosis and organoid modeling, which extends the present discussion with translational disease context.

Applications, Limits & Misconceptions

A 83-01 is widely applied in:

• Dissecting TGF-β/Smad pathway function in cancer, fibrosis, and stem cell differentiation (Saito et al., 2025).
• Preventing EMT during epithelial cell expansion in organoid and regenerative medicine protocols.
• Modulating cellular growth inhibition and apoptosis in tumor microenvironment studies.
• Optimizing in vitro differentiation of hiPSCs into mature intestinal epithelial lineages.

Compared to prior reviews that focus on basic pathway suppression, this article updates practical parameters and benchmarks for direct application in stem cell/organoid workflows.

Common Pitfalls or Misconceptions

• Non-selectivity at high concentrations: At >3 μM, A 83-01 begins to suppress BMP4-induced transcription, potentially confounding pathway-specific analyses (APExBIO).
• Water insolubility: The compound is insoluble in water and must be dissolved in DMSO or, with warming/sonication, in ethanol; improper preparation can affect experimental outcomes.
• Long-term solution instability: Stock solutions should not be stored long-term; compound degradation may affect potency and reproducibility (APExBIO).
• Misapplication in non-TGF-β pathways: A 83-01 is not intended for inhibition of BMP-only signaling or unrelated kinase pathways.
• Assuming pan-kinase inhibition: Despite ALK-4/7 activity, the compound is not broadly active against all serine/threonine kinases.

For troubleshooting and protocol optimization, see this stepwise guide, which offers advanced workflow strategies beyond the scope of this overview.

Workflow Integration & Parameters

Preparation: Dissolve A 83-01 at ≥21.1 mg/mL in DMSO; heat at 37°C for 10 min or sonicate if needed. Ethanol solubility is ≥9.82 mg/mL with gentle warming/ultrasound. The compound is insoluble in water and should be aliquoted and stored below -20°C; avoid repeated freeze-thaw cycles (APExBIO).

Recommended working concentration: 0.1–1 μM for TGF-β pathway suppression in cell-based and organoid assays, based on literature benchmarks and empirical optimization.

Controls: Always include DMSO vehicle controls and, where possible, parallel BMP pathway agonists/antagonists to confirm selectivity.

Application protocol: For EMT inhibition or stem cell maintenance, add A 83-01 at the start of culture and maintain dosing per protocol duration (typically 24–72 hours for acute studies; up to 2 weeks for chronic pathway suppression). For detailed troubleshooting in cell viability/proliferation assays, see this practitioner case study, which clarifies real-world cytotoxicity and selectivity outcomes compared to the present article’s focus on application breadth.

Conclusion & Outlook

A 83-01 (SKU A3133) from APExBIO is a well-characterized, high-purity ALK-5 inhibitor enabling robust, selective inhibition of TGF-β-induced Smad-dependent transcription. Its high selectivity and reproducibility position it as a core reagent in EMT, fibrosis, and stem cell/organoid research workflows. Careful attention to concentration, solubility, and storage is required for optimal results. Ongoing advances in organoid modeling and in vitro pharmacokinetics highlight the need for such validated small-molecule tools. For further mechanistic details and advanced protocol guidance, this article extends and updates previous overviews by integrating direct evidence from peer-reviewed research and product certifications.

For compound specifications, technical support, and ordering information, visit the A 83-01 product page.